Abstract
We have demonstrated that stimulation of ETB receptors may enhance cerebral blood flow and provide neuroprotection; however, the mechanism of action of these receptors in cerebral ischemia has not been determined. Selective activation of ETB receptors by IRL-1620 may provide neuroprotection following cerebral ischemia by reducing oxidative stress and promoting angiogenesis. Cerebral ischemia was produced in male Sprague-Dawley rats by permanently occluding the middle cerebral artery. Animals were treated with either vehicle or IRL-1620 (5µg/kg, i.v.) at 2, 4 and 6 hours after occlusion. The role of ETB receptors was confirmed by treating rats with ETB antagonist, BQ788 (1 mg/kg, i.v.) and then administering vehicle or IRL-1620 following cerebral ischemia. After 24h, rats were assessed for neurological and motor deficit, and the brains were removed to determine the effects on infarct volume, oxidative stress, neuronal numbers and cerebral vasculature. Vehicle-treated rats presented with an infarct volume of 153.23 ± 32.18 mm3 along with marked neurological and motor deficit and a decrease in neuronal nuclei (PConclusions: Activation of ETB receptors via IRL-1620 reduced neurological damage, infarct volume, and oxidative stress, while increasing VEGF following cerebral ischemia in rats. These results demonstrate that selective ETB receptor activation may be a novel neuroprotective therapy in the treatment of cerebral ischemia.